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Abstract
Background: Activation of human resting T lymphocytes results in an immediate increase in
protein synthesis. The increase in protein synthesis after 16–24 h has been linked to the increased
protein levels of translation initiation factors. However, the regulation of protein synthesis during
the early onset of T cell activation has not been studied in great detail. We studied the regulation
of protein synthesis after 1 h of activation using α CD3 antibody to stimulate the T cell receptor
and α CD28 antibody to provide the co-stimulus.
Results: Activation of the T cells with both antibodies led to a sustained increase in the rate of
protein synthesis. The activities and/or phosphorylation states of several translation factors were
studied during the first hour of stimulation with α CD3 and α CD28 to explore the mechanism
underlying the activation of protein synthesis. The initial increase in protein synthesis was
accompanied by activation of the guanine nucleotide exchange factor, eukaryotic initiation factor
(eIF) 2B, and of p70 S6 kinase and by dephosphorylation of eukaryotic elongation factor (eEF) 2.
Similar signal transduction pathways, as assessed using signal transduction inhibitors, are involved
in the regulation of protein synthesis, eIF2B activity and p70 S6 kinase activity. A new finding was
that the p38 MAPK α /β  pathway was involved in the regulation of overall protein synthesis in
primary T cells. Unexpectedly, no changes were detected in the phosphorylation state of the cap-
binding protein eIF4E and the eIF4E-binding protein 4E-BP1, or the formation of the cap-binding
complex eIF4F.
Conclusions: Both eIF2B and p70 S6 kinase play important roles in the regulation of protein
synthesis during the early onset of T cell activation.
Background
The initiation of translation of mRNAs is an important
control point in protein synthesis in eukaryotes and re-
quires a set of initiation factors (eIFs). The cap-binding
protein eIF4E recognises the 5'cap-structure of the mRNA,
and is a component of the eIF4F complex consisting of
eIF4E, eIF4G, a scaffolding protein [1,2], and eIF4A, an
RNA helicase [3,4]. Any secondary structure in the 5'un-
translated region of the mRNA is thought to be unwound
by eIF4A together with eIF4B or eIF4H [5]. The 40S subu-
nit of the ribosome binds to the eIF4F complex through
an association between eIF4G and eIF3, which interacts
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directly with the 40S ribosomal subunit. The preinitiation
complex, containing the 40S ribosomal subunit, eIF4F,
eIF4B, and Met-tRNAi•eIF2•GTP, scans the 5'UTR until
the AUG start codon is located. The subsequent hydrolysis
of the GTP bound to eIF2 is promoted by eIF5, after which
eIF2•GDP leaves the ribosome. The 60S ribosomal subu-
nit can then join and the 80S complex is formed. eIF2 in
the GDP-bound state is inactive and, in order to return to
the active form again, the GDP is exchanged for GTP in a
step promoted by the guanine nucleotide exchange factor
eIF2B.
The next stage in the translation process, the elongation
step, can be regulated via changes in the activity of eEF2
[6]. Phosphorylation of eEF2 at Thr56 results in its com-
plete inactivation [7].
Human primary T-cells are metabolically quiescent, with
little ongoing DNA, RNA or protein synthesis [8–10]. The
low protein synthesis rate in quiescent T cells is associated
with low levels of initiation factors in these cells. The rate
of protein synthesis increase 2–4 fold after 4 h of mitogen-
ic stimulation [11], and it has been reported that the
mRNA and protein levels for several translation initiation
factors increased during T cell activation. The mRNA levels
of eIF4A, eIF2α , and eIF4E increased rapidly after stimula-
tion [12]. However, the increase in the levels of the corre-
sponding protein lagged significantly behind. It is
therefore likely that increased levels of translation factors
contribute to the pronounced stimulation of protein syn-
thesis that occurs during T cell activation at later times,
while modulation of the activity of several translation in-
itiation factors e.g. by phosphorylation or association
with binding proteins is important in the early phase of T
cell activation [13].
Increased phosphorylation of eIF4E in T lymphocytes has
been reported under several conditions. Activation of qui-
escent mature porcine peripheral blood mononuclear
cells with phorbol 12-myristate 13-acetate (PMA) or con-
canavalin A [14] or stimulation of human primary T cells
with PHA [15], PMA, or PMA plus ionomycin [16] caused
a rapid increase in the phosphorylation of eIF4E. Similar-
ly, stimulation of the T cell receptor in the human leukae-
mic T cell line Jurkat with OKT-3, or treatment with PMA,
increased eIF4E phosphorylation [14,17], and a signifi-
cant increase in the amount of eIF4F complexes was also
detected.
The activity of eIF4E can also be modulated by its associ-
ation with eIF4E-binding proteins, of which 4E-BP1 is the
best-studied. Phosphorylation of 4E-BP1 leads to its dis-
sociation from eIF4E, leaving eIF4E free to bind eIF4G and
form eIF4F complexes [18,19]. In a murine cytotoxic T cell
line, interleukin-2 induced the phosphorylation of 4E-
BP1 [20]. 4E-BP1 is present in human primary T lym-
phocytes [21] and becomes phosphorylated in response
to PMA or PMA plus io nomycin [16].
In several cell lines, an increase in eIF2B activity coincides
with an increase in protein synthesis [22,23]. One mech-
anism to regulate the activity of eIF2B is via phosphoryla-
tion of its ε -subunit (eIF2Bε ) by GSK-3, which causes a
decrease in eIF2B activity [24]. Stimulation of T cells with
PMA plus ionomycin caused a rapid rise in eIF2B activity,
which coincided with inactivation of GSK-3 [25], suggest-
ing a role for dephosphorylation of eIF2Bε . The activity of
eIF2B can also be modulated by phosphorylation of the α -
subunit of eIF2. eIF2 phosphorylated in its α -subunit acts
as a competitive inhibitor of eIF2B [26]. Stimulation of T
cells with PHA did not cause significant changes in the
phosphorylation state of eIF2α  [15], excluding this mech-
anism of regulation under this condition.
In this study we used the antibodies, α CD3 and α CD28,
to activate resting human primary T lymphocytes. Engage-
ment of α CD3 activates the T cell receptor, while cross-
linking of α CD28 with the B7 receptor will supply a co-
stimulatory signal, which is required for full activation of
a resting T cell [27,28]. We have studied the effects of T cell
activation on protein synthesis and on the activities and/
or phosphorylation states of several translation initiation
factors. Furthermore, the signalling pathways involved in
these changes have been investigated.
Results
Activation of primary T cells with a physiological stimulus 
increased protein synthesis
We activated T cells with the antibodies, α CD3 and
α CD28, for up to 24h and measured protein synthesis
and the activation of several signalling pathways that are
important for the regulation of translation factors and
that have been shown to increase after activation of T cells
[29] (Fig. 1).
The rate of protein synthesis in resting T cells is low, and
activation of the cells with α CD3 and α CD28 led to a sub-
stantial increase in the incorporation of [35S]-methionine
into protein. Within 24 h of activation, the rate of protein
synthesis was increased 6-fold (Fig. 1A), depending on the
blood donor.
After 30 min of activation, phosphorylation of ERK and
p38 MAPK, and the activity of PKB were measured. Phos-
phorylation of ERK2 and p38 MAPK increased already af-
ter 5 min and reached a maximum after 30–60 min of
treatment (data not shown). After 30 min of treatment, a
clear phosphorylation of ERK and p38MAPK was detected
(Fig. 1B). Treatment with PMA, a potent activator of PKC,
was used as a positive control. PMA induced, in particular,BMC Biochemistry 2002, 3  http://www.biomedcentral.com/1471-2091/3/11
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Figure 1
Activation of T cells with α CD3 and α CD28. A. Primary T lymphocytes were activated with both α CD3 and α CD28 for
4, 8, 16 or 24 h and for the last 45 min 10 µCi/ml of [35S]-labelled methionine was present. The experiment was performed in
duplicate. Incorporation of [35S]-labelled methionine into equal amounts of protein was measured. Protein synthesis in control
cells was set at 100%. Methionine incorporation ranged between 1000 and 2000 cpm per 50 µg of protein. (control cells at t =
0 h and t = 24 h are not significantly different, n = 3). B. T cells were activated by α CD3 and α CD28 or with PMA. Cells were
activated for 30 min, harvested and 50–80 µg of lysate was analyzed by SDS-PAGE and Western blotting. Antibodies that rec-
ognize the phosphorylated form of either ERK (pp42) or p38 MAPK (pp38) were used. Even loading of the gel was verified
using anti-ERK2 (p42). Similar results were obtained in three sets of experiments. C. PKB activity was measured as described
in Materials and Methods (p<0.05, n=4).BMC Biochemistry 2002, 3  http://www.biomedcentral.com/1471-2091/3/11
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a greater extent of phosphorylation of ERK than α CD3
plus α CD28. For p38 MAPK phosphorylation, the differ-
ence between these stimuli was less pronounced (Fig. 1B).
An 1.5 fold increase in PKB activity (Fig. 1C) was detected
within 30 min of activation of T cells by α CD3 and
α CD28.
The increase in protein synthesis and the stimulation of
various signalling pathways indicated that treatment of T
cells with α CD3 and α CD28 led to activation of the cells.
The cellular protein levels of eIF4E and eIF2Bε  do not 
change during the early phase of T cell activation
Previous studies using mitogenic stimuli showed that the
levels of several initiation factor proteins increase later
(>16 h) following T cell activation and probably contrib-
ute to the increase in protein synthesis [15,16,25]. To ex-
amine whether activation of T cells with α CD3 and
α CD28 also affected initiation factor levels, the amounts
of the cap-binding protein, eIF4E, and of the catalytic sub-
unit of the eIF2B complex, eIF2Bε , were assessed at differ-
ent time points (Fig. 2). The amounts of eIF4E and eIF2Bε
protein each remained constant during the first 6 h.
In this study, we have focused on the mechanisms under-
lying the initial response after activation of primary T cells
by α CD3 and α CD28 and the concomitant increase in
protein synthesis. Since the levels of initiation factor pro-
teins did not change in this early phase of T cell activation,
we considered the possibility that changes in the phos-
phorylation state and/or activities of several translation
factors were involved in the initial activation of protein
synthesis in T cells.
Protein synthesis is regulated via multiple signalling path-
ways
Primary T lymphocytes were activated with α CD3 and
α CD28, and after 1 h of activation, protein synthesis was
increased 1.2 fold (Fig. 3). To study the signalling events
involved in this increase in protein synthesis, we per-
formed the experiment in the presence of different specific
signal transduction pathway inhibitors (Fig. 3). The in-
crease in overall protein synthesis was consistently
blocked by each of the signal transduction inhibitors
used, i.e. the PI 3-kinase inhibitor wortmannin, the
mTOR inhibitor rapamycin, the p38 MAPKα /β  inhibitors
SB203580 and SB202190, and the MEK inhibitor
PD98059. It appears that the immediate activation of pro-
tein synthesis in T cells involves interplay between several
signalling pathways.
Stimulation of T cells with the more potent stimulus PMA
for 1 h led to a substantially larger increase in protein syn-
thesis (1.8 fold) compared to activation with α CD3 and
α CD28 (Fig. 3).
Figure 2
The amount of eIF4E and eIF2Bε  protein did not
change in the early phase of T cell activation. T cells
were activated with α CD3 and α CD28 for the indicated
times. In each case, 600 µg of protein was used for an
m7GTP Sepharose pull down to detect the amount of eIF4E
or used in an immunoprecipitation reaction with α eIF2Bε
coupled to protein G to detect eIF2Bε . The pull downs were
analyzed by SDS-PAGE and Western blotting. The experi-
ment was performed in duplicate. Figure 3
The increase in protein synthesis requires signalling
via several pathways. T cells were preincubated with
wortmannin (W, 100 nM), rapamycin (R, 100 nM), SB203580
(10 µM), SB202190 (10 µM) or PD98059 (PD, 50 µM) for 30
min before activation with both α CD3 and α CD28 for 1 h or
the cells were treated with PMA (1 µM) for 1 h. For the last
30 min of activation 10 µCi/ml [35S]-labelled methionine was
present. The experiment was performed in duplicate. Protein
synthesis in control cells was set at 100%. Methionine incor-
poration ranged between 600 and 1500 cpm per 50 µg of
protein. Incorporation of [35S]-labelled methionine into equal
amounts of protein was measured using hot TCA precipita-
tion (p<0.05 for the α CD3/28 and PMA treated samples; all
other samples are not significantly different from the control,
n=6).BMC Biochemistry 2002, 3  http://www.biomedcentral.com/1471-2091/3/11
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Phosphorylation of eIF4E, eIF4F complex formation and 
4E-BP1 phosphorylation remain unchanged after T cell ac-
tivation
Phosphorylation of the cap-binding protein eIF4E can be
regulated via the ERK and p38 MAPKα /β pathways
[17,30], two pathways that appear to be important for the
regulation of protein synthesis in T cells (Fig. 3). Further-
more, the phosphorylation of eIF4E has been reported to
be increased in response to several different treatments of
primary T lymphocytes [15,16] or the Jurkat T cell line
[14,17]. However, activation of T cells with α CD3 and
α CD28 for up to 60 min did not cause a significant
change in the phosphorylation state of eIF4E (Fig. 4A).
Stimulation of T cells with either α CD3 or α CD28 alone
was also insufficient to change the phosphorylation state
of eIF4E (data not shown). We did detect a marked change
in phosphorylation of eIF4E after 30 min of PMA treat-
ment, indicating that the cells respond to this stimulus
(Fig. 4A). In addition, treatment of the Jurkat T cell line
with α CD3 and α CD28 caused phosphorylation of eIF4E
that was already detectable after 30 min, demonstrating
the effectiveness of the antibodies (α CD3 and α CD28)
used (Fig. 4A).
An important way of regulating eIF4F assembly is through
eIF4E-binding proteins such as 4E-BP1. Phosphorylation
of 4E-BP1 leads to its release from eIF4E, allowing the lat-
ter protein to bind eIF4G [31]. The phosphorylation of
4E-BP1 can be detected by virtue of a reduction in its mo-
bility upon SDS-PAGE [18,19]. As a control to demon-
strate that different forms of human 4E-BP1 can be
resolved on our gel system, we used HeLa cell extract and
in this case three separate bands (α , β  and γ ) were indeed
detected (Fig. 4B), indicative of differently phosphorylat-
ed forms. In resting T-cells, 4E-BP1 was mainly present in
the unphosphorylated form (α -form) as reported before
[32]. We were unable to detect any changes in mobility of
4E-BP1, and therefore its phosphorylation after stimula-
tion of the cells with α CD3 plus α CD28 or PMA (Fig. 4B).
Formation of eIF4F complexes was studied by purification
of eIF4E on m7GTP-Sepharose followed by a Western blot
to detect associated eIF4G. In resting T cells, eIF4F com-
plexes are already present, and after 1h of activation with
α CD3, α CD28, or both antibodies, the amount of eIF4G
bound to eIF4E remained unchanged (Fig. 4C). Similar re-
sults were obtained after 30 min of activation (data not
shown). Surprisingly, no 4E-BP1 associated with eIF4E
was detected, even though up to 2 mg of T cell extract was
used in a m7GTP Sepharose pull down (data not shown).
This could be due to low amounts of 4E-BP1 protein
present in resting T cells.
These data indicate that increased formation of eIF4F
complexes is not required for the activation of protein
synthesis in the early phase of T cell activation.
Regulation of eIF2B activity after activation of T cells
In several cell types, an increase in overall protein synthe-
sis coincides with an increase in eIF2B activity [22,23,25].
We therefore examined the activity of eIF2B after activa-
tion of primary T cells (Fig. 5A). After 1 h of activation
with α CD3 and α CD28, the activity of eIF2B increased 2.2
fold. The increase in eIF2B activity was not caused by a
change in the phosphorylation state of the α -subunit of
eIF2 (Fig. 5B) or by an increase in the amount of eIF2Bε
protein (Figs. 2 and 5B and 5E). Immunoprecipitation of
different amounts of T cell extracts showed that the eIF2Bε
antibody was able to detect different levels of protein in
the immunoprecipitations within the same range used in
Fig. 5B (bottom panel). Taken these results together it sug-
gested that eIF2B was regulated directly, e.g. via phospho-
rylation. To study which signal transduction pathways are
involved in the regulation of the activity of eIF2B, the cells
were activated in the presence of specific signal transduc-
tion pathway inhibitors and eIF2B activity was measured.
The basal activity of eIF2B was slightly affected in the pres-
ence of the PI 3-kinase inhibitor wortmannin, the mTOR
inhibitor rapamycin, and the p38 MAPKα /β  inhibitor
SB203580, however the α CD3 plus α CD28-induced in-
crease in eIF2B activity was completely blocked in the
presence of each inhibitor. The MEK inhibitor PD98059
did not affect the basal eIF2B activity and was also able to
inhibit the α CD3 and α CD28-induced increase in eIF2B
activity, showing that all these signalling pathways are re-
quired to mediate the activation of eIF2B (Fig. 5A).
Activation of eIF2B after stimulation of the cells with PMA
was about 2 fold higher than after stimulation with the
antibodies. An increase in eIF2B activity after stimulation
of primary T-cells with PMA/ionomycin has been reported
before [16,25].
It has been suggested that GSK-3 may be an important reg-
ulator of eIF2B activity, i.e. in response to insulin [33,34]
and during cell survival [35]. Phosphorylation of eIF2Bε
by GSK-3 inhibits the activity of the eIF2B complex [33].
GSK-3 activity is decreased only by a small extent (15%)
after T cell activation with α CD3 and α CD28 (Fig. 5D). In
contrast, PMA treatment reduced GSK-3 activity by about
50%, which is similar to previously reported data.
GSK-3 phosphorylates eIF2Bε  on Ser540. Therefore, we
analyzed the phosphorylation state of this site using a
phospho-specific antibody. We were unable to detect any
change in the phosphorylation of this site (Fig. 5E) in re-
sponse to α CD3 and α CD28, excluding a role for GSK-3BMC Biochemistry 2002, 3  http://www.biomedcentral.com/1471-2091/3/11
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Figure 4
Regulation of eIF4E phosphorylation and eIF4F formation. A. Jurkat T cells were activated for 30 or 60 min by both
α CD3 and α CD28. The primary T lymphocytes were activated for the indicated times with both α CD3 and α CD28 or with
PMA. eIF4E was purified using m7GTP Sepharose, analyzed on a one-dimensional iso-electric focusing gel and detected by
Western blotting. 4E and 4E-P indicate unphosphorylated and phosphorylated eIF4E respectively. B. 100 µg of total cell lysate
from primary T cells treated for 1 h with α CD3 and α CD28 or PMA was analyzed by SDS-PAGE and Western blotting to
detect 4E-BP1. (-) indicates untreated cells. The lane with 4E-BP1 from HeLa cell extract was obtained from a shorter expo-
sure from the same blot. C. Formation of eIF4F was analyzed after 60 min activation of primary T cells with either α CD3,
α CD28 or both. eIF4E was purified as described above and its association with eIF4G was analyzed by SDS-PAGE and Western
blotting. An eIF4E blot was used to verify equal loading of all lanes. Similar results for eIF4E, eIF4G and 4E-BP1 were obtained
in three independent experiments.BMC Biochemistry 2002, 3  http://www.biomedcentral.com/1471-2091/3/11
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Figure 5
Regulation of eIF2B activity. A. T cells were preincubated with wortmannin (W, 100 nM), rapamycin (R, 100 nM),
SB203580 (SB, 10 µM), or PD98059 (PD, 50µM) for 30 min and left untreated (white bar) or the cells were activated with both
α CD3 and α CD28 (black bar) for 1 h. Simultaneously cells were activated with PMA (hatched bar) for 1 h. An eIF2B assay was
performed as described in Materials and Methods. Bars marked with * are significantly different from the untreated cells (p <
0.05, n = 5). B. Cell lysates from resting and stimulated cells (1 h α CD3 and α CD28) were analyzed by SDS-PAGE and West-
ern blotting to detect phosphorylated eIF2α . eIF2B was immunoprecipitated from 400 µg of lysate using α eIF2Bε  and the
amount of protein was analyzed by SDS-PAGE and Western blotting. Similar results were obtained in three experiments C. To
test the sensitivity of the eIF2Bε  antibody different amounts of T cell extracts (as indicated) were immunoprecipitated with
α eIF2Bε  and analyzed by SDS-PAGE and Western blotting. Similar results were obtained in two experiments. D. T cells were
left untreated (white bar) or the cells were activated with both α CD3 and α CD28 (black bar) or PMA (grey bar) for 1 h. GSK-
3α  and β  were immunoprecipitated together from 400 µg of lysate and a kinase assay was performed as described in Materials
and Methods (p<0.05, n=4). E. eIF2Bε  was immunoprecipitated from 400 µg of lysate from resting and stimulated cells (1 h
α CD3 and α CD28) and the total amount of eIF2Bε  and the phosphorylation state of Ser540 were analyzed by SDS-PAGE and
Western blotting. Similar results were obtained in two experiments.BMC Biochemistry 2002, 3  http://www.biomedcentral.com/1471-2091/3/11
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in the regulation of eIF2B activity in T cells under these
conditions.
Dephosphorylation of eEF2
Elongation factor 2 (eEF2) plays an important role in the
regulation of the rate of elongation, and therefore in the
regulation of the rate of overall protein synthesis. Phos-
phorylation of eEF2 causes its inactivation [7]. Phosphor-
ylation of eEF2 was rapidly but only transiently decreased
after activation of the primary T lymphocytes with α CD3
and α CD28 (Fig. 6). Within 3 min, maximum dephos-
phorylation was reached and the phosphorylation level
returned to a level similar to that of resting T cells by 10
min. Given the transient nature of these changes, it is un-
likely that regulation of eEF2 plays a role in the sustained
increase in the rate of protein synthesis after activation of
T cells. However, dephosphorylation of eEF2 could play a
role very early in T cell activation.
Regulation of p70 S6 kinase upon T cell activation
Activation of p70 S6 kinase and phosphorylation of the ri-
bosomal protein S6, an in vivo substrate of p70 S6 kinase,
coincide with increased translation of specific mRNAs,
namely the 5'TOP mRNAs [36]. However, a recent report
has questioned the role of p70 S6 kinase in 5'TOP messen-
ger translation [37].
We studied the effect of activation of T cells with α CD3
plus α CD28 on these proteins. The activity of p70 S6 ki-
nase was increased about 1.5 fold after 60 min, and the in-
crease in p70 S6 kinase activity was blocked by each of the
signal transduction inhibitors used, i.e. wortmannin,
PD98059, SB203580, and rapamycin (Fig. 7A). Similar re-
sults were obtained when the phosphorylation of the S6
protein was examined as a cellular read-out of p70 S6 ki-
nase activity (Fig. 7B). Phosphorylation of S6 in response
to PMA was greater than in response to α CD3 and
α CD28, similarly to the situation for several translation
factors, as described above.
Discussion
The mechanisms underlying the regulation of protein syn-
thesis following activation of resting primary T cells has
not been widely studied. Early reports showed that stimu-
lation of primary T cells with pharmacological stimuli,
e.g. PHA or PMA, led to an increase in protein synthesis
and protein levels of certain translation initiation factors
within 16 h [15,16,25,38,39]. More recently the regula-
tion of protein synthesis and translation factors after a 6 h
stimulation of primary T cells with PMA or PMA/ionomy-
cin was described in detail [16].
We investigated the regulation of protein synthesis and
translation factors during the early phase of activation of
resting T cells by α CD3 and α CD28, i.e. 1 h of activation.
The protein synthesis rate in T cells rapidly increased after
Figure 6
Dephosphorylation of eEF2 after T cell activation. T
cells were activated with α CD3 and α CD28 for the indicated
times. 80 µg of protein was analyzed by SDS-PAGE and
Western blotting. Phosphorylation of eEF2 was detected
using a phospho-specific antibody (eEF2-P). ERK2 was
detected as a loading control. Similar results were obtained
in three experiments.
Figure 7
Regulation of p70 S6 kinase. A. Primary T lymphocytes
were preincubated with wortmannin (W, 100 nM), rapamy-
cin (R, 100 nM), SB203580 (SB, 10 µM), or PD98059 (PD, 50
µM) for 30 min before activation with both α CD3 and
α CD28 (black bars) for 60 min. Bars marked with * are sig-
nificantly different (p<0.01) from the activity in untreated
cells (n=4). B. T cells were preincubated with wortmannin
(W, 100 nM), rapamycin (R, 100 nM), SB203580 (SB, 10 µM),
or PD98059 (PD, 50 µM) for 30 min before activation with
both α CD3 and α CD28 for 60 min or the cells were stimu-
lated with PMA for 60 min. Phosphorylation of the S6 protein
was analyzed by SDS-PAGE and Western blotting using a
phospho-specific S6 (Ser235) antibody. Similar results were
obtained in four experiments.BMC Biochemistry 2002, 3  http://www.biomedcentral.com/1471-2091/3/11
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treatment (Fig. 1), and several signalling pathways, i.e.
ERK and p38 MAPK phosphorylation and PKB activation,
were stimulated, showing the efficacy of the α CD3 and
α CD28 antibodies in activating the cells.
The increase in protein synthesis after 1 h was mediated
via multiple signalling pathways, e.g. the MEK, p38 MAP-
Kα /β , PI 3-kinase and mTOR pathway, as indicated by the
use of signal transduction inhibitors (Fig. 3). In several
cell types, the involvement of either MEK [40–44], PI 3-ki-
nase [23,40,45,46] or mTOR [23,40,45–47] in the activa-
tion of protein synthesis has been described. However,
this is the first time that a role for the p38 MAPKα /β path-
way (Fig. 3) in the regulation of overall protein synthesis
has been described. This role is supported by the fact that
two structurally unrelated p38 MAPKα /β  inhibitors, i.e.,
SB202190 and SB203580, were each able to block the in-
crease in protein synthesis.
The increase in protein synthesis after activation of T cells
with α CD3 and α CD28 coincided with an increase in the
activities of p70 S6 kinase and eIF2B and dephosphoryla-
tion of eEF2, which is indicative of an increase in its activ-
ity [7]. The dephosphorylation of eEF2 (Fig. 6) was very
transient, and therefore it is unlikely that eEF2 plays an
important role in the sustained increase in protein synthe-
sis after T cell activation. However, activation of eEF2
could be important for the initial increase in protein syn-
thesis.
The stimulation of p70 S6 kinase was mediated via similar
signalling pathways (Fig. 7) to those underlying the acti-
vation of overall protein synthesis. Inhibition of PI 3-ki-
nase, mTOR, p38 MAPKα /β , or MEK during T cell
activation by α CD3 and α CD28 prevented the activation
of p70 S6 kinase, indicating that multiple signalling path-
ways are required for regulation of p70 S6 kinase activity.
The effect of rapamycin on the activation of p70 S6 kinase
in response to α CD3 and α CD28 has been reported previ-
ously [48]. Inhibition of the activation of p70 S6 kinase by
SB203580 has been described before in insulin-stimulat-
ed rat vascular smooth muscle cells [43,49–51]. Further-
more, it has been reported that SB203580 (at the
concentration used, 10 µM) can inhibit phosphorylation
of PKB at Threonine308 and thus its activation [52,53].
Since PKB is an upstream component of the signalling
pathway towards p70 S6 kinase, this could provide a
mechanism by which SB203580 blocks activation of p70
S6 kinase.
Each of the other signalling pathways studied here has
also been implicated in the regulation of p70 S6 kinase ac-
tivity in a variety of cell types under a range of conditions
[43,49–51]. However, in human primary T cells all of
them appear to be important for the regulation of p70 S6
kinase activity after stimulation with α CD3 and α CD28.
The activity of the guanine nucleotide exchange factor,
eIF2B, also was mediated via similar signalling pathways
as the increase in protein synthesis (Fig. 5).
The increase in eIF2B activity after activation of T cells
with α CD3 and α CD28, at the early times we examined,
was not due to an increase in eIF2B protein level or to
changes in eIF2α  phosphorylation. Therefore, modifica-
tion of the eIF2B protein complex probably caused the in-
crease in eIF2B activity. The modulation of the activity of
the eIF2B complex after activation of T cells with α CD3
and  α CD28 required several different signalling path-
ways, e.g. MEK, p38 MAPKα /β , mTOR and the PI 3-kinase
pathway. These signalling pathways have been reported
separately to be involved in the regulation of eIF2B activ-
ity [16,23,42,44,54]. However, this is the first report
where all these pathways are involved in the regulation of
eIF2B in a single cell type.
A small inactivation of GSK-3 was detected after activation
of primary T cells with α CD3 and α CD28. However, no
dephosphorylation of Ser540 in eIF2Bε  was detected (Fig.
5E), excluding a role for GSK-3 in regulating the activity of
eIF2B under these conditions. In contrast, studies employ-
ing PMA/ionomycin-activated T cells [25], insulin treat-
ment of various cell types [34], and cell survival [35] have
implied a role for GSK-3 in regulating eIF2B activity.
In contrast to previously reported data using mitogenic
stimuli to activate primary T cells or Jurkat T cells [14–17],
eIF4E phosphorylation, association of eIF4G with eIF4E
and 4E-BP1 phosphorylation remained unchanged after T
cell activation using α CD3 and α CD28 as a stimulus (Fig.
4). Signal transduction inhibitor studies showed that the
MEK and p38 MAPKα /β  pathways are important for eIF4E
phosphorylation in Jurkat T cells [17], and a role for MEK
was demonstrated previously in primary T cells [16]. The
weaker activation of the ERK pathway in particular (Fig. 1)
by α CD3 and α CD28 in primary T cells may well account
for the absence of increased phosphorylation of eIF4E un-
der these conditions.
We did not observe increased phosphorylation of 4E-BP1
in response to α CD3 and α CD28, even though it has been
reported to occur after cytokine stimulation of a murine
cytotoxic T cell line [20] or after 6 h of mitogenic stimula-
tion of human primary T cells [16]. However, Grolleau et
al.[32] showed that 4E-BP1 was present in primary T cells
mainly in its dephosphorylated form, and no significant
change was detected after PMA treatment. Our results are
consistent with this last finding; 4E-BP1 is mainly present
as one band, and no change in mobility is observed uponBMC Biochemistry 2002, 3  http://www.biomedcentral.com/1471-2091/3/11
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cell treatment. This is consistent with the observation that
eIF4F complex formation did not alter. However, it re-
mains surprising that eIF4F complexes are present when
4E-BP1 is completely dephosphorylated, and therefore
presumably associated with eIF4E. We were unable to de-
tect any 4E-BP1 associated with eIF4E, which is probably
due to the low 4E-BP1 protein levels in resting T lym-
phocytes, thus explaining basal eIF4F formation.
Conclusions
The treatment of primary T lymphocytes with α CD3 and
α CD28 activates two key components of the translational
machinery, p70 S6 kinase and eIF2B. The activities of
these translation factors were regulated similarly to the ac-
tivation of protein synthesis, consistent with an important
role for the components in the activation of protein syn-
thesis by α CD3 and α CD28. Interestingly, activation of
protein synthesis, p70 S6 kinase, and eIF2B is inhibited by
rapamycin, a compound that was first discovered as an
immunosuppressant, suggesting that mTOR regulated
translation is involved in the process of T cell prolifera-
tion. The activation of p70 S6 kinase is related to the reg-
ulation of translation of specific mRNAs, while the
activation of eIF2B is likely to be required for stimulation
of general protein synthesis [13]. This suggests that in-
creases in both specific and general protein synthesis are
important in the early phase of T cell activation.
Materials and methods
Primary T cell isolation and cell treatment
Buffy coats used for the isolation of T cells were prepared
from freshly drawn blood from healthy human donors
and were obtained from the Scottish National Blood
Transfusion Service (Edinburgh, UK). Mononuclear leu-
kocytes were isolated by Ficoll-Hypaque (Amersham-
Pharmacia) gradient centrifugation. T cells were further
enriched using nylon-wool columns. T cells were sus-
pended in RPMI 1640 medium supplemented with 10%
(v/v) heat-inactivated foetal calf serum, 1 mM glutamine
and antibiotics/antimycotics (100 units/ml penicillin G
sodium, 100 µg/ml streptomycin sulphate and 0.25 µg/ml
amphotericin B). The cells were kept in 75 cm2 tissue cul-
ture flasks at a density of 4 ×  106 cells/ml at 37°C and 5%
CO2. All tissue culture reagents were obtained from Gibco
BRL.
Measurement of protein synthesis rate
Cells were treated with α CD3 mouse IgG2a mAb (33/
2A3) (1:1000 dilution from a hybridoma supernatant)
and  α CD28 mouse IgM mAb (CK243) (1:12 dilution
from a hybridoma supernatant) for 1 h in the absence or
presence of signal transduction inhibitors. For the last 30
min, 10 µCi/ml [35S]methionine was added to the cells.
To harvest the cells, the cells were transferred to a micro-
fuge tube and centrifuged at 6000 ×  g for 20 s. The cell pel-
let was lysed in 20 mM Hepes pH7.4, 50 mM β -
glycerophosphate, 0.2 mM EDTA, 1% Triton X-100, 10%
(v/v) glycerol, 1 µg/ml leupeptin, 1 µg/ml pepstatin, 1 µg/
ml antipain, 1 mM benzamidine, and 1 mM DTT. Part of
the sample was used to measure the protein content with
Protein Assay Reagent (Bio-Rad) and the rest was spotted
in duplicate on to Whatman 3 MM paper and subjected to
'hot TCA precipitation'.
Gel electrophoresis and Western blotting
T cells were activated with α CD3 and α CD28 for times in-
dicated in the figure legends, harvested in Laemmli sam-
ple buffer and analyzed by SDS-PAGE and Western
blotting. Phospho-p42/44(ERK) and phospho-p38 MAPK
antibodies were obtained from New England Biolabs, the
phospho-eIF2α antibody was a kind gift from Dr. Gary
Krause (Detroit, USA), the phospho-S6 (Ser235) antibody
was a kind gift from Dr. Dario Alessi (University of Dun-
dee), the 4E-BP1 antibody was obtained from Santa Cruz
(SC-6025), the eIF2Bε  antibody was raised in rabbit
against the whole protein expressed in the baculovirus
system [44], the phospho-specific antibody for Ser540 in
eIF2Bε  was raised against the peptide SEEPDS(P)RGGC
(S(P) indicates the phosphoserine) in sheep, and the
phospho-eEF2 (Thr56) antibody was raised against the
peptide GETRFT(P)DTRK (T(P) indicates phosphothreo-
nine) [55].
Kinase assays
For PKB assays, the cells were pelleted at 6000 × g for 20 s
and harvested in 50 mM Tris-HCl pH 7.5, 1 mM sodium
orthovanadate, 1 mM EDTA, 1 mM EGTA, 1% Triton X-
100, 50 mM NaF, 5 mM sodium pyrophosphate, 0.27 M
sucrose, 1 µM microcystin LR, 1 µg/ml leupeptin, 1 µg/ml
pepstatin, 1 µg/ml antipain, and 1 mM benzamidine-HCl.
Antibodies directed against the three PKB isoforms (α , β ,
and γ ) were simultaneously bound to protein G-Sepha-
rose, and about 100 µg of protein was used in immuno-
precipitation reactions. The immunoprecipitation and
PKB assays were performed as described before [56].
For p70 S6 kinase and GSK-3 assays, the cells were har-
vested in a buffer containing 50 mM Tris-HCl pH 7.5, 50
mM β -glycerophosphate, 0.5 mM sodium vanadate, 1.5
mM EDTA, 1.5 mM EGTA, 0.5% Triton X-100, 1 µg/ml le-
upeptin, 1 µg/ml pepstatin, 1 µg/ml antipain, 1 mM ben-
zamidine, and 1 mM DTT. A polyclonal antibody raised
against a peptide sequence from p70 S6 kinase-1 was
bound to protein G-Sepharose, and about 100 µg of ex-
tract was used in the immunoprecipitation reaction. Im-
munoprecipitation and the p70 S6 kinase assays (using a
peptide substrate) were performed as described before
[57]. GSK-3α  and β  were immunoprecipitated together
from 150 µg of cell lysate and kinase assays were per-
formed as described [23,58].BMC Biochemistry 2002, 3  http://www.biomedcentral.com/1471-2091/3/11
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Phosphorylation of eIF4E and eIF4F complex formation
Cells were pelleted at 6000 ×  g for 20 s and harvested in a
buffer containing 20 mM Hepes pH7.4, 50 mM β -glycero-
phosphate, 0.2 mM EDTA, 1% Triton X-100, 10% (v/v)
glycerol, 1 µg/ml leupeptin, 1 µg/ml pepstatin, 1 µg/ml
antipain, 1 mM benzamidine, and 1 mM DTT. Using m7
GTP Sepharose 4B (Amersham-Pharmacia; 15 µl of slurry
diluted with 15 µl of Sepharose CL-4B), eIF4E was puri-
fied from approximately 2 mg of extract. For SDS-PAGE,
Laemmli sample buffer was added and the samples were
heated at 95°C for 10 min. For one-dimensional iso-elec-
tric focusing analysis, the appropriate sample buffer was
added [59]. The samples were run on a 12.5% SDS-PA gel
or on a one-dimensional iso-electric focusing gel, trans-
ferred to PVDF, and detected by Western analysis. eIF4E
was detected with a polyclonal antibody raised in rabbit
[43], and eIF4GI with a polyclonal antibody raised in
sheep against the peptide CKKEAVGDLLDAFKEAN.
Measurement of eIF2B activity
The cells were pelleted at 6000 ×  g for 20 s and lysed in a
buffer containing 20 mM Tris-HCl pH 7.5, 50 mM β -glyc-
erophosphate, 100 mM KCl, 0.2 mM sodium orthovana-
date, 0.2 mM EDTA, 0.2 mM EGTA, 1% Triton X-100,
10% glycerol, 1 µg/ml leupeptin, 1 µg/ml pepstatin, 1 µg/
ml antipain, 1 mM benzamidine, and 1 mM DTT. About
50 µg of cell lysate was used for the eIF2B assay, which was
performed as described previously [23].
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